Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

Zai Lab and Pfizer have entered a strategic collaboration to commercialise XACDURO (sulbactam-durlobactam), a new ...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab (“Zai Lab”, NASDAQ: ZLAB; HKEX: 9688) and Pfizer (“Pfizer”, NYSE: PFE) announced today a strategic ...

Zai Lab accelerates innovative drug launches in China through partnerships and expertise, targeting $1.5-$2B revenue by 2028.

Pfizer, however, added that as part of the research ... pathogens new functions that could be harmful if released from a lab. Typically, this has meant experiments in which there is a reasonable ...

The Pfizer lease marks an anomaly in a local life science real estate market that has cooled significantly since the early stages of the pandemic when there was a feverish demand for lab space.

The alliance between PostEra and Pfizer over the past three years has already advanced several small-molecule programs, and the AI Lab itself was built on a pre-existing Generative Chemistry ...

Thanks to generous support and partnership from Alexandria Real Estate Equities, Inc., Fred Hutch has a new, state-of-the-art ...

This site is home to Pfizer’s growing oncology business and a program that offers lab space and resources to biotech startups. Pfizer’s new lease at Torrey Heights is a significant step down ...

Pfizer has been tapped by Shanghai-based Zai Lab to help market the company’s antibacterial drug Xacduro in mainland China, the partners said Thursday. The companies did not disclose the ...